Angiopoietin-2 is increased in sepsis and inversely associated with nitric oxide-dependent microvascular reactivity by Davis, Joshua S et al.
RESEARCH Open Access
Angiopoietin-2 is increased in sepsis and
inversely associated with nitric oxide-dependent
microvascular reactivity
Joshua S Davis
1,2, Tsin W Yeo
1, Kim A Piera
1, Tonia Woodberry
1, David S Celermajer
3, Dianne P Stephens
4,
Nicholas M Anstey
1,2*
Abstract
Introduction: Angiopoietin-2 (ang-2), an angiogenic peptide released by endothelial cell Weibel-Palade bodies
(WPBs), increases endothelial activation and vascular permeability. Ang-2 is raised in severe sepsis but the
mechanisms underlying this are not known. Nitric oxide (NO) inhibits WPB exocytosis, and bioavailability of
endothelial NO is decreased in sepsis. We hypothesized that endothelial NO bioavailability would be inversely
correlated with ang-2 concentrations in sepsis.
Methods: Plasma ang-2, vascular endothelial growth factor (VEGF) and endothelial-active cytokines were assessed
in 83 patients with early sepsis and 41 hospital controls, and related to reactive hyperaemia-peripheral arterial
tonometry, RH-PAT, a measure of endothelial NO bioavailability.
Results: Plasma Ang-2 was elevated in sepsis (median [interquartile range (IQR)], ng/ml: severe sepsis 12.4
[8.5-33.4], sepsis without organ failure 6.1 [5.0-10.4], controls 2.7 [2.2-3.6], P < 0.0001). It correlated inversely with
RH-PAT (r = -0.38, P < 0.0001) and positively with IL-6 (r = 0.57, P < 0.0001) and degree of organ failure (sequential
organ function assessment score) (r = 0.58, P < 0.0001). The correlation of ang-2 with RH-PAT persisted after
controlling for sepsis severity. In a longitudinal mixed-effects model, recovery of RH-PAT over time was associated
with decline in ang-2.
Conclusions: Ang-2 is elevated in proportion to sepsis severity, and inversely correlated with NO-dependent
microvascular reactivity. Impaired endothelial NO bioavailability may contribute to increased endothelial cell release
of ang-2, endothelial activation and capillary leak. Agents that increase endothelial NO bioavailability or inhibit WPB
exocytosis and/or Ang-2 activity may have therapeutic potential in sepsis.
Introduction
Microvascular and endothelial dysfunction are central to
the pathophysiology of sepsis, contributing to organ dys-
function even in the setting of normal post-resuscitation
haemodynamics [1]. Angiopoietin-2 (ang-2), an angio-
genic peptide, activates endothelial cells and increases
vascular inflammation. It functions as an autocrine med-
iator of the endothelium and is stored predominantly in
endothelial cells [2]. Ang-2 is a ligand of the tyrosine
kinase receptor, Tie-2, and antagonises the angiopoietin
1-induced Tie-2 receptor autophosphorylation responsi-
ble for the maintenance of endothelial cell quiescence
[3]. This results in endothelial cells being sensitized to
the effects of pro-inflammatory cytokines and vascular
endothelial growth factor (VEGF), resulting in a loss of
endothelial cell quiescence and an increase in vascular
activation and inflammation.
Levels of circulating ang-2 have been shown to be
raised in human sepsis [4-6] and, more recently, to cor-
relate with mortality [7-9] and pulmonary vascular leak
[10,11]. Despite a growing interest in ang-2 in sepsis,
the mechanisms underlying elevated ang-2 levels in
patients with sepsis are unclear. Ang-2 is co-packaged
with von Willebrand Factor (vWF) within endothelial
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released upon endothelial cell stimulation and WPB
exocytosis [12]. In-vitro studies demonstrate that exocy-
tosis of WPBs can be triggered by multiple secretago-
gues, including thrombin, histamine, epinephrine, VEGF,
and hypoxia [13]. However, there are only two known
inhibitors of WPB release: nitric oxide (NO) and hydro-
gen peroxide (H2O2), of which NO is thought to be the
most important [14].
We have recently demonstrated impaired microvascu-
lar reactivity in patients with sepsis by reactive hyperae-
mia peripheral arterial tonometry (RH-PAT) [15], which
is at least 50% NO-dependent and thus provides an esti-
mate of endothelial NO bioavailability [16]. In contrast
to earlier hypotheses suggesting major overproduction
of NO in patients with sepsis [17], there is now increas-
ing evidence that systemic NO production is normal or
decreased in humans with sepsis [18,19]. Impaired
endothelial NO bioavailability may underlie increased
WPB exocytosis in sepsis, and thus the release of ang-2
from endothelial cells. However, the relation between
endothelial NO bioavailability and measures of WPB
release in sepsis has not been determined. We hypothe-
sized that plasma ang-2 levels in patients with sepsis
would be raised in proportion to disease severity and
would be inversely related to endothelial NO bioavail-
ability, as estimated by RH-PAT.
Materials and methods
Study design and setting
We performed a prospective observational study at a
350-bed teaching hospital in tropical Australia, with an
18-bed mixed ICU. Prior approval was obtained from
the Human Research Ethics Committee of the Menzies
School of Health Research and the Department of
Health and Community Services. Written informed con-
sent was obtained from all participants or their next of
kin where necessary.
Participants
The study subjects were adults (≥ 18 years) hospitalized
with sepsis, who were enrolled in a previously reported
study of microvascular reactivity; more detail of subject
recruitment, patient characteristics and study procedures
are provided in this paper [15]. Some of the data
included in the current paper have been previously
reported (RH-PAT index, intra-cellular adhesion mole-
cule-1 [ICAM1], E-selectin and IL-6), but are included
here for comparison with Ang-2. Sepsis was defined as a
proven or suspected infection plus at least two criteria
for the systemic inflammatory response syndrome
(SIRS) present within the past four hours [20]. Septic
patients were eligible for enrolment within 24 hours of
their admission to the ICU, or within 36 hours of
admission to the ward. Exclusion criteria were: coagulo-
pathy (platelets ≤ 20 × 10
9/L, activated partial thrombo-
plastin time ≥ 70 seconds, international normalized ratio
≥ 2.0); smoking of tobacco within the preceding four
hours; and receipt of intravenous nitrates. Control sub-
jects were adults recruited from hospital patients with
no clinical or laboratory evidence of inflammation or
infection, and who had not met SIRS criteria within the
past 30 days. Septic patients were prospectively classified
as severe sepsis, or sepsis without organ failure. Severe
sepsis was defined as sepsis with organ dysfunction or
shock at the time of enrolment according to American
College of Chest Physicians/Society of Critical Care
Medicine consensus criteria [15,20].
Laboratory assays
Venous blood was collected in lithium heparin tubes at
baseline and two to four days later, and plasma was fro-
zen at -80°C. Control patients had blood collected at
baseline only. Plasma concentrations of VEGF, ICAM-1
and E-selectin were measured by ELISA (R&D Systems,
Minneapolis, MN, USA), according to the manufac-
turer’s instructions. The ELISA used to determine
plasma Ang-2 concentrations (R&D Systems, Minneapo-
lis, MN, USA) reports a lower limit of detection of
8.3 pg/ml (0.0083 ng/ml), with coefficients of variation
for intra-assay and inter-assay precision of 4.2% and
7.4%, respectively.
IL-6 and TNFa were measured by flow cytometry
using a cytokine bead array (CBA; BD Biosciences,
Franklin Lakes, NJ, USA).
Measurement of microvascular reactivity/endothelial NO
bioavailability
Microvascular reactivity was measured at the bedside by
RH-PAT (Itamar Medical, Caesarea, Israel), a non-inva-
sive method of assessing endothelial function [21], which
is at least 50% dependent on endothelial NO production
[16]. We have previously reported internal validation and
repeatability of RH-PAT in acute inflammatory states
[22]. PAT was measured in a fingertip before and after a
five-minute ischemic stress at the forearm, generating an
RH-PAT index, normalized to the control arm, as pre-
viously described [15]. All studies were performed after
resuscitation and at least an hour of hemodynamic stabi-
lity in a quiet room at 25°C, with the patient in a recum-
bent position.
Statistical methods
All analyses were hypothesis based and were specified
ap r i o r i . Continuous variables were compared using
Student’s t-test/analysis of variance or Mann Whitney
U test/Kruskal-Wallis test for parametric and non-
parametric variables, respectively. Categorical variables
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and CBA assays, values below the lower limit of detection
were assigned a value of halfway between zero and
the lower limit of detection for the purposes of analysis.
Correlates with baseline Ang-2 were determined using
Spearman’s coefficient. For multivariate analysis, linear
regression with backward selection was used. All indepen-
dent variables with a Wald P-value of less than 0.10 on
univariate analysis, or which were considered biologically
important were included in the initial model. Variables
with a Wald P-value of 0.05 or more were sequentially
dropped from the model. The natural logarithm of Ang-2
was used as the dependent variable, because Ang-2
was right-skewed and log transformation lead to a normal
distribution. To control for covariates in the relationship
between Ang-2 and RH-PAT index, the covariate in ques-
tion was added to a linear regression model with log Ang-
2 as the independent variable and RH-PAT index as the
dependent variable. To examine longitudinal correlations,
linear mixed-effects models were used. A two-sided
P value of less than 0.05 was considered significant. All
analyses were performed using Stata version 10 (Stata
Corp, College Station, TX, USA).
Results
Participants
Eighty five patients with sepsis and 45 control patients
were enrolled in the study. Two sepsis patients and four
controls were excluded from further analysis because
they refused blood collection. Of the remaining 83 sepsis
patients, 52 had organ dysfunction due to sepsis at base-
line (severe sepsis group) and 31 did not (sepsis without
organ failure). The three groups were well matched in
terms of risk factors for endothelial dysfunction and
other baseline characteristics (Table 1).
Baseline Ang-2 and VEGF
Plasma Ang-2 concentrations were raised in sepsis in pro-
portion to disease severity (Table 2 and Figure 1a). Median
Ang-2 concentrations (ng/ml (interquartile range (IQR))
were two-fold higher in patients with severe sepsis (12.4
(8.5 to 33.4)), than in those with sepsis without organ fail-
ure (6.1 (5.0 to 10.4); P < 0.0001), and 4.5-fold higher
than in controls (2.7 (2.2 to 3.6), P < 0.0001). The differ-
ence in Ang-2 between sepsis without organ failure and
controls was also significant (P < 0.0001). VEGF was
also raised in sepsis patients compared with controls
(P = 0.0001, Table 2 and Figure 1b), but the difference
in VEGF between severe sepsis and sepsis without organ
failure was not significant.
Ang-2 and disease severity
Ang-2 correlated with sepsis severity (Table 3), as mea-
sured by Acute Physiology and Chronic Health Evalua-
tion (APACHE) II score (r = 0.46, P < 0.0001), Sequential
Organ Failure Assessment( S O F A )s c o r e( r=0 . 5 8 ,
P < 0.0001), number of organ failures (r = 0.48,
P < 0.0001) and arterial lactate (r = 0.41, P =0 . 0 0 3 ) ,
whereas VEGF did not correlate with any of these para-
meters. As neutrophils release H2O2,w ea l s oe x a m i n e d
the relation between neutrophil counts and plasma Ang-
2 concentrations, and found no significant correlation
(r = 0.16, P = 0.15).
Ang-2 and NO-dependent microvascular reactivity
On univariate analysis, Ang-2 was inversely correlated
with RH-PAT index, an estimate of endothelial NO
bioavailability (r = -0.38, P < 0.0001), and positively cor-
related with markers of endothelial activation (ICAM-1
r=0 . 5 8 ,P ≤ 0.0001, E-selectin r = 0.53, P < 0.0001).
VEGF did not correlate with endothelial NO
Table 1 Baseline characteristics of participants
Severe sepsis Sepsis without organ failure Control P value across all groups
N 52 31 41
Age (years)
a 52.8 (48.6-56.9) 50.8 (46.5-55.2) 47.3 (43.2-51.6) NS
c
Male n (%) 31 (60) 21(68) 28 (68) NS
d
Diabetic n (%) 17 (33) 7 (23) 13 (32) NS
d
Smoker n (%) 26 (50) 12 (39) 16 (39) NS
d
IHD n (%) 9 (17) 6 (19) 5 (12) NS
d
On a statin n (%) 13 (25) 9 (29) 11 (27) NS
d
APACHE II
b 19 (15-25) 8 (5-11) 0.0001
e
SOFA score
b 6 (3-9) 1 (0-2) 0.0001
e
a. Mean (95% confidence interval).
b. Median (Interquartile range).
c. By one-way analysis of variance.
d. By Fisher’s exact test across all three groups.
e. By Kruskal-Wallis test.
APACHE II, Acute Physiology and Chronic Health Evaluation II score; IHD, ischemic heart disease; NS, not significant; SOFA, Sequential Organ Failure Assessment score.
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The relationship between log Ang-2 and RH-PAT index
remained significant after controlling for disease severity
using SOFA score.
In a longitudinal analysis, plasma Ang-2 concentrations
decreased significantly between day 0 (median (IQR)
10.16 (5.32 to 19.39)) and day two to four (8.72 (5.38 to
15.73), P = 0.01; Table 4). RH-PAT index increased over
the same time period, but the change was not statistically
significant (Day 0 mean index 1.67 (95% confidence
i n t e r v a l( C I ) :1 . 5 5t o1 . 7 8 ) ,d a yt w ot of o u r=1 . 8 5( 1 . 7 0
to2.00)). In a mixed-effects linear regression model,
increase in RH-PAT index over the first two to four
days correlated significantly with fall in Ang-2 (r = 0.45,
P < 0.0001); change in RH-PAT index over time did not
correlate with VEGF, ICAM-1, E-selectin, SOFA score,
or IL-6.
Ang-2 and markers of inflammation
Plasma TNFa was below the lower limit of detection in
the majority of patients in both the sepsis and control
groups (Table 2). In those in whom it was detectable
(≥ 2.8 pg/ml), there was no relation between Ang-2 and
TNFa (r = 0.24, P = 0.44). Ang-2 correlated with IL-6
(r = 0.57, P < 0.0001), but not with C-reactive protein
or white blood cell count.
Multivariate analysis of correlates of angiopoietin-2
The variables included in the initial multivariate linear
regression model, with log Ang-2 as the dependent vari-
able, were: RH-PAT index, serum albumin, APACHE
and SOFA scores, plasma concentrations of E-selectin,
ICAM-1, IL-6 and IL-10, and peripheral blood platelet
and white blood cell counts. The independent variables
that remained significant in the final model, along with
their b coefficients (95% CI) were: RH-PAT index (b =
-0.35 (-0.64 to -0.06)), ICAM-1 (ng/ml, b =3 . 8×1 0
-4
(1.4 to 6.3 × 10
-4)), IL-6 (pg/ml, b =1 . 7×1 0
-4 (0.05 to
2.9 × 10
-4)), platelet count (× 10
9/L, b =- 2×1 0
-3 (-3.2
to -0.90 × 10
-3)), and white blood cell count (× 10
9/L,
b = 3.2 × 10
-2 (1.1 to 5.2 × 10
-2)).
Outcomes
The median (IQR) length of stay in the ICU among all
sepsis patients was 5.4 (3.0 to 8.4) days, and this was
significantly correlated with baseline Ang-2 (r = 0.30,
P = 0.03). Of the 83 patients with sepsis, only 8 had died
at 28-day follow up (10%). Seven of these were from the
severe sepsis group (28-day mortality 13%) and one was
from the sepsis without organ failure group (mortality
3%). Baseline levels of Ang-2 were not significantly differ-
ent (P = 0.32) in those with fatal (11.46 (7.09 to 45.12))
and non-fatal outcomes (10.04 (5.26 to 18.96)).
Discussion
Plasma Ang-2 concentrations are raised in patients with
sepsis, in proportion to disease severity and endothelial
cell activation, and are inversely associated with
estimated endothelial NO bioavailability both at baseline
and during recovery. This finding supports the hypoth-
esis that impaired endothelial NO bioavailability in
sepsis leads to increased exocytosis of WPBs, release of
Ang-2, and thus to further endothelial cell sensitization
and activation. This hypothesis is also supported by
recent findings in patients with severe malaria, where
an increase in endothelial NO bioavailability over time
(also measured by RH-PAT) was significantly associated
with falling plasma Ang-2 levels [23].
Table 2 Baseline measurements according to disease category
Severe sepsis Sepsis without organ failure Control P value across all groups
N 52 31 41
Angiopoietin 2 (ng/ml)
a 12.44 (8.47-33.44) 6.11 (4.59-10.37) 2.71 (2.15-3.61) 0.0001
d
VEGF (pg/ml)
a 98.4 (56.4-142.6) 80.8 (57.5-147.3) 52.3 (31.8-73.5) 0.0007
d
Plasma ICAM-1 (ng/ml)
a 846 (523-1483) 501 (368-672) 323 (265-393) 0.0001
d
Plasma E-selectin (ng/ml)
a 200.5 (113-478) 87.0 (50.8-164.4) 38.4 (26.9-58.2) 0.0001
d
RH-PAT index
b 1.57 (1.44-1.71) 1.85 (1.67-2.03) 2.07 (1.93-2.22) <0.0001
e
Plasma interleukin 6 (pg/ml)
a 385.1 (124.2-996.0) 148.3 (45.9-315.0) 5.0 (2.2-8.1) 0.0001
d
Plasma TNFa ≥ 2.8 pg/ml (n,%)
c 8 (22) 4 (14) 5 (17) NS
f
a. Median (Interquartile range).
b. Mean (95% confidence interval).
c. 2.8 pg/ml is the lower limit of detection for the assay used for TNFa.
d. By Kruskal-Wallis test.
e. By oneway analysis of variance.
f. By Fisher’s exact test across all three groups.
ICAM-1, intra-cellular adhesion molecule-1; NS, not significant; RH-PAT, reactive hyperemia peripheral arterial tonometry; TNFa, tumor necrosis factor a; VEGF,
vascular endothelial growth factor.
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tion between estimated endothelial NO bioavailability
and plasma Ang-2 concentrations in sepsis, there is sub-
stantial recent evidence underpinning this hypothesis.
In vitro, NO is the only substance demonstrated to
reduce exocytosis of WPBs and release of Ang-2 apart
from high concentrations of H2O2 [13,14]. NO reduces
WPB exocytosis by facilitating the S-nitrosylation of
N-ethyl-malemide sensitive factor (NSF), which results
i nt h ei n a b i l i t yo ft h eW P Bm e m b r a n et of u s ew i t ht h e
plasma membrane [2,12,13]. Furthermore, contrary to
previously accepted theories, there is increasing evidence
that systemic NO production is normal or decreased
rather than increased in sepsis [18,19], and that sepsis is
a state of imbalance between the endothelial and induci-
ble isoforms of NO synthase in the microvasculature,
resulting in a relative deficiency of endothelial NO
[24,25]. The fact that non-specific NO inhibitors
increase mortality in patients with sepsis [26] supports
this idea, and it is possible that increased Ang-2 release
is one of the mechanisms underlying this finding.
Clinical studies investigating the endothelium in sepsis
commonly use circulating markers of endothelial cell
activation as a surrogate measure of endothelial func-
t i o n .W eh a v ep r e v i o u s l ys h o w nt h a tI C A M - 1a n d
E-selectin, two of the most commonly used markers of
endothelial activation in sepsis, do not correlate with
endothelial function as measured by RH-PAT [15]. In
contrast, Ang-2 correlates with endothelial function as
Figure 1 Baseline plasma angiopoietin-2 and vascular
endothelial growth factor across disease categories. (a) Baseline
plasma angiopoietin-2. (b) Vascular endothelial growth factor. Solid
circles represent individual sepsis subjects and solid triangles
represent control subjects. Horizontal lines through the data points
represent group median values. P values indicate pairwise
comparisons between groups as indicated. NS, not significant; VEGF,
vascular endothelial growth factor.
Table 3 Correlations of baseline plasma angiopoietin-2 in
sepsis patients
Spearman’s rho P n
Endothelial function and activation
RH-PAT index -0.38 <0.0001 74
VEGF -0.04 NS 80
ICAM-1 0.58 <0.0001 83
E-Selectin 0.53 <0.0001 83
Markers of inflammation
IL-6 0.57 <0.0001 66
C-reactive protein 0.16 NS 82
Markers of disease severity
SOFA score 0.58 <0.0001 82
APACHE II score 0.46 <0.0001 83
Number of organ failures 0.48 <0.0001 83
Arterial lactate 0.41 0.003 51
APACHE II score, Acute Physiology and Chronic Health Evaluation II Score;
ICAM-1, intra-cellular adhesion molecule-1; IL-6, interleukin 6; NS, not
significant; RH-PAT, reactive hyperemia peripheral arterial tonometry; SOFA,
Sequential Organ Failure Assessment score; VEGF, vascular endothelial growth
factor.
Table 4 Change in angiopoietin-2 and other variables
over time
Day 0 Day 2-4 P value
a
RH-PAT
b 1.67 (1.55-1.78) 1.83 (1.67-1.99) NS
SOFA score
c 4 (2-8) 3 (1-7) 0.07
Ang-2 (ng/ml)
c 10.16 (5.32-19.39) 8.72 (5.38-15.73) 0.01
VEGF (pg/ml)
c 94.8 (57.0-143.8) 73.6 (48.6-167.3) NS
ICAM-1 (ng/ml)
c 655.6 (448.0-1084.1) 694.0 (450.3-1258.1) NS
E-selectin (ng/ml)
c 154.5 (69.1-396.3) 120.3 (63.9-199.2) <0.0001
IL-6 (pg/ml)
c 224.4 (75.0-595.5) 58.1 (17.2-255.8) <0.0001
a. Mean (95% confidence interval).
b. Median (Interquartile range).
c. Wilcoxon’s paired signrank test.
Ang-2, angiopoietin-2; ICAM-1, intra-cellular adhesion molecule-1; IL-6,
interleukin 6; NS, not significant; RH-PAT, reactive hyperemia peripheral
arterial tonometry; SOFA, Sequential Organ Failure Assessment score; VEGF,
vascular endothelial growth factor.
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ally. Thus Ang-2 is a more meaningful biomarker of
endothelial cell function in sepsis than currently used
surrogate measures.
Endothelial cell activation in sepsis increases vascular
leak, triggers a pro-coagulant state, up-regulates adhesion
molecule expression, and further drives the inflammatory
response [27]. Together, these processes cause regional
hypoperfusion and acute organ dysfunction. By mediating
autocrine activation of local endothelial cells, Ang-2 may
exacerbate tissue hypoperfusion and inflammation, pro-
viding a plausible mechanism for its independent associa-
tion with organ failure and mortality in sepsis [7].
In-vitro studies of Ang-2 demonstrate that in the
absence of Ang-2, a TNFa concentration of 40 pg/ml or
more is required to independently activate endothelial
cells, whereas in the presence of Ang-2 at a concentra-
tion of 2000 pg/ml, a TNFa concentration of 5 pg/ml
or more is able to cause endothelial activation [28].
Plasma TNFa levels in sepsis patients in this study were
relatively low, with only 1 of 69 sepsis patients having
TNFa levels of 40 pg/ml or more, similar to the low
levels reported in other sepsis studies [29,30]. The con-
centrations of Ang-2 in this and other human sepsis stu-
dies [4,5,7] are higher than those used in in-vitro
studies, and may sensitize endothelial cells to lower con-
centrations of TNFa. Furthermore, local microvascular
TNFa concentrations may be higher than we and others
have found in plasma. Nevertheless, taken together our
results support the hypothesis that in sepsis, Ang-2 sen-
sitizes endothelial cells to the effects of cytokines that
may otherwise cause only minimal or no endothelial
activation [28].
The factors triggering Ang-2 release from WPBs in
sepsis are not known. Thrombin [12], VEGF [31] and,
in some [31,32], but not other studies [4,12], TNFa,
cause WPB release in-vitro.H o w e v e r ,w ef o u n dt h a t
neither TNFa nor VEGF correlated with Ang-2.
Although we found a strong independent association
between IL-6 and Ang-2, IL-6 has not been shown to
cause exocytosis of WPBs or secretion of Ang-2 in vitro.
IL-6 is an important pro-inflammatory cytokine and
correlates with disease severity in sepsis. Bacterial lipo-
polysaccharide increases Ang-2 levels [33] and drives IL-
6 expression [30], and such factors may account for this
association.
Although Ang-2 correlated with length of stay in this
study, it did not correlate with mortality. Despite a med-
ian APACHE II score of 19, and a consequent predicted
mortality of 34.8% [34], there were few deaths in our
study (8 in total, 13% within the severe sepsis group).
This is consistent with the previously reported low mor-
tality from severe sepsis in our ICU [35], and suggests
that our study was under-powered to examine the rela-
tion between Ang-2 and mortality. However, in studies
with higher numbers of deaths, Siner and colleagues and
Kumpers and colleagues both found a clear association
between plasma Ang-2 levels and risk of mortality [7,8].
Although we did not directly measure endothelial cell
NO concentrations (which is not possible in septic
patients), RH-PAT index is an indirect measurement of
NO bioavailability and is at least 50% NO-dependent in
healthy volunteers [16]. Other methods of measuring
NO in patients with sepsis, such as plasma NO metabo-
lites, are not specific to the endothelium and are con-
founded by nitrate retentioni nr e n a lf a i l u r e[ 3 6 ] .T h u s
i ti sn o tp o s s i b l et od i r e c t l yc o n f i r mt h er e l a t i o n
between endothelial NO bioavailability and plasma Ang-
2 using currently available methods in humans with
sepsis.
The correlation between Ang-2 and RH-PAT index
was statistically significant but was not strong. We can-
not exclude an alternative explanation for the inverse
association between Ang-2 and endothelial NO bioavail-
ability: that increased Ang-2 release in sepsis leads to
decreased NO bioavailability as a consequence of upre-
gulated endothelial cell inflammation and superoxide-
mediated NO quenching. Nevertheless the clear in vitro
evidence for NO as the major inhibitor of WPB exocy-
tosis and Ang-2 release, and the findings in other
disease settings such as malaria [23], make it more likely
that impaired NO bioavailability is a significant contri-
butor to Ang-2 release in sepsis.
vWF is co-packaged with Ang-2 in WPBs but is also
released by activated platelets, and is thus less specific
for endothelial cells. Although not measured in our
study, plasma vWF activity is known to be increased in
patients with sepsis, and to correlate with mortality [37].
Like other markers of endothelial cell activation, vWF
has not been compared with measures of endothelial
NO bioavailability in sepsis. However, in non-septic
patients with risk factors for cardiovascular disease,
vWF is raised, correlates with endothelial activation as
measured by E-selectin [38], and is inversely propor-
tional to endothelial NO bioavailability as estimated by
flow-mediated dilatation of the brachial artery [39].
Furthermore, plasma vWF is raised in proportion to
plasma Ang-2 in patients with sepsis and acute lung
injury [11]. Because our results suggest that impaired
endothelial NO bioavailability exacerbates WPB release,
they provide a plausible explanation for the increase in
both Ang-2 and vWF in patients with sepsis.
Conclusions
In conclusion, Ang-2 is raised in sepsis in proportion
to disease severity and correlates with endothelial
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cular reactivity, both at baseline and over the first two
to four days of treatment. This suggests that decreased
endothelial NO bioavailability may contribute to Ang-2
release by reducing negative feedback on WPBs, thus
augmenting endothelial cell activation and contributing
to organ dysfunction. Adjunctive therapies which
improve endothelial NO, decrease WPB release, or
antagonise Ang-2 may have roles in reducing organ dys-
function and improving mortality in sepsis.
Key messages
￿ Plasma concentrations of Ang-2, an angiogenic pep-
tide, have been shown to be raised in patients with
sepsis and to correlate with organ failure and mortal-
ity, but the underlying mechanisms are unclear.
￿ In-vitro, NO inhibits Ang-2 release from endothe-
lial cells. In this study, plasma concentrations of
Ang-2 in septic patients were raised in proportion to
disease severity, and were inversely proportional to
estimated endothelial NO bioavailability.
￿ Decreased endothelial NO bioavailability in sepsis
m a yb et h em e c h a n i s mf o rr a i s e dA n g - 2c o n c e n t r a -
tions, thus contributing to capillary leak and organ
dysfunction.
￿ Adjunctive therapies that improve endothelial NO
or antagonise Ang-2 may have roles in reducing
organ dysfunction and improving mortality in sepsis.
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